242 related articles for article (PubMed ID: 31495903)
1. CRISPR/Cas9 gene correction of HbH-CS thalassemia-induced pluripotent stem cells.
Yingjun X; Yuhuan X; Yuchang C; Dongzhi L; Ding W; Bing S; Yi Y; Dian L; Yanting X; Zeyu X; Nengqing L; Diyu C; Xiaofang S
Ann Hematol; 2019 Dec; 98(12):2661-2671. PubMed ID: 31495903
[TBL] [Abstract][Full Text] [Related]
2. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
[TBL] [Abstract][Full Text] [Related]
3. Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in β-Thalassemia-induced Pluripotent Stem Cells.
Niu X; He W; Song B; Ou Z; Fan D; Chen Y; Fan Y; Sun X
J Biol Chem; 2016 Aug; 291(32):16576-85. PubMed ID: 27288406
[TBL] [Abstract][Full Text] [Related]
4. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
[TBL] [Abstract][Full Text] [Related]
5. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
6. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
[TBL] [Abstract][Full Text] [Related]
7. Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.
Li L; Yi H; Liu Z; Long P; Pan T; Huang Y; Li Y; Li Q; Ma Y
Stem Cell Res Ther; 2022 Mar; 13(1):102. PubMed ID: 35255977
[TBL] [Abstract][Full Text] [Related]
8. Efficient gene correction of an aberrant splice site in β-thalassaemia iPSCs by CRISPR/Cas9 and single-strand oligodeoxynucleotides.
Xiong Z; Xie Y; Yang Y; Xue Y; Wang D; Lin S; Chen D; Lu D; He L; Song B; Yang Y; Sun X
J Cell Mol Med; 2019 Dec; 23(12):8046-8057. PubMed ID: 31631510
[TBL] [Abstract][Full Text] [Related]
9. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
10. Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived iPSCs Using CRISPR/Cas9.
Wattanapanitch M
Methods Mol Biol; 2021; 2211():193-211. PubMed ID: 33336279
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 (D10A) nickase-mediated Hb CS gene editing and genetically modified fibroblast identification.
Wu WH; Ma XM; Huang JQ; Lai Q; Jiang FN; Zou CY; Chen LT; Yu L
Bioengineered; 2022 May; 13(5):13398-13406. PubMed ID: 36700476
[TBL] [Abstract][Full Text] [Related]
12. Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9.
Park CY; Sung JJ; Cho SR; Kim J; Kim DW
Stem Cell Reports; 2019 Jun; 12(6):1242-1249. PubMed ID: 31105049
[TBL] [Abstract][Full Text] [Related]
13. Application of an expanded multiplex genotyping assay for the simultaneous detection of Hemoglobin Constant Spring and common deletional alpha-thalassemia mutations.
Kidd JL; Azimi M; Lubin B; Vichinsky E; Hoppe C
Int J Lab Hematol; 2010 Aug; 32(4):373-80. PubMed ID: 19919622
[TBL] [Abstract][Full Text] [Related]
14. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.
Tang ZH; Chen JR; Zheng J; Shi HS; Ding J; Qian XD; Zhang C; Chen JL; Wang CC; Li L; Chen JZ; Yin SK; Huang TS; Chen P; Guan MX; Wang JF
Stem Cells Transl Med; 2016 May; 5(5):561-71. PubMed ID: 27013738
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 system and its applications in human hematopoietic cells.
Hu X
Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
[TBL] [Abstract][Full Text] [Related]
16. First Case of a Compound Heterozygosity for Two Nondeletional α-Thalassemia mutations, Hb Constant Spring and Hb Quong Sze.
Zhou JY; Yan JM; Li J; Li DZ
Hemoglobin; 2016 Jun; 40(3):210-2. PubMed ID: 26956449
[TBL] [Abstract][Full Text] [Related]
17. DNA studies are necessary for accurate patient diagnosis in compound heterozygosity for Hb Adana (HBA2:c.179>A) with deletional or nondeletional α-thalassaemia.
Tan JAMA; Kho SL; Ngim CF; Chua KH; Goh AS; Yeoh SL; George E
Sci Rep; 2016 Jun; 6():26994. PubMed ID: 27271331
[TBL] [Abstract][Full Text] [Related]
18. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
19. Derivation of the human induced pluripotent stem cell line MUi017-A from a patient with homozygous Hemoglobin Constant Spring.
Wongkummool W; Maneepitasut W; Munkongdee T; Tong-Ngam P; Tangprasittipap A; Svasti S; Kitiyanant N; Paiboonsukwong K; Fucharoen S; Tubsuwan A
Stem Cell Res; 2017 Apr; 20():84-87. PubMed ID: 28395746
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9-Based Genome Editing of Human Induced Pluripotent Stem Cells.
Giacalone JC; Sharma TP; Burnight ER; Fingert JF; Mullins RF; Stone EM; Tucker BA
Curr Protoc Stem Cell Biol; 2018 Feb; 44():5B.7.1-5B.7.22. PubMed ID: 29512106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
